According to a story from Newswise, Holly Becker was only 24 years old when she was first diagnosed with non-Hodgkin lymphoma. However, her life was saved with a stem cell…
.jpg)
Diffuse large B-cell lymphoma (DLBCL) is a common type of non-Hodgkins lymphoma. World Pharma News recently reported that the FDA approved the first chemoimmunotherapy, Polivy, for DLBCL in combination with…
According to a story from statnews.com, new, groundbreaking forms of treatment, such as gene therapy and CAR-T cell therapy, are giving patients with rare genetic disorders and advanced cancers more…
.jpg)
Each year over eighteen thousand people in the United States are diagnosed with diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin lymphoma. A recent FDA news release…
According to a story from Science Daily, a review of studies focused on allogeneic stem cell transplants as a treatment for non-Hodgkin lymphoma found that it wasn't possible to conclude…
.jpg)
The Asco Post recently interviewed Dr. Jean Pierre Bizzari, the Executive Vice President of Celgene, a multinational bioparmaceutical company. The interview covered various aspects of research and development (R&D)…
According to a story from globenewswire.com, the biopharmaceutical company TG Therapeutics, Inc. recently made an announcement declaring that the US Food and Drug Administration (FDA) had awarded the company Orphan…
Phase 1 Trial A Phase 1 trial by Gamida Cell is examining a new potential treatment option for patients with multiple myeloma and relapsed/refractory non-Hodgkin's lymphoma who have not responded…
A grandmother of four in Maryland has recently become the first cancer patient to complete the experimental CAR-T cell procedure at Georgetown University Hospital. Daisy Diggs 67, who was…
Each year the Food and Drug Administration approves dozens of new therapies to fulfill unmet needs for various patient populations. It's just been published that in 2018 they approved a…
The US Food and Drug Administration recently announced the approval of the first biosimilar drug for patients with non-Hodgkin lymphoma in a press release. The drug is known as Truxima…
According to a story from investors.amgen.com, the drug developer Amgen recently announced its intent to present all new clinical trial data which will feature its latest work in testing a…
After their own personal struggles with cancer, the Rendina family are working to raise money and awareness to fight the disease. For more information, you can view the source press…
According to a story from Morningstar, Richard Rendina and his family are no strangers to the challenges and tragedy that can come with a cancer diagnosis. Bruce Redina, for example…
© Copyright Patient Worthy
